Literature DB >> 458157

Immune response in subacute sclerosing panencephalitis: reduced antibody response to the matrix protein of measles virus.

S L Wechsler, H L Weiner, B N Fields.   

Abstract

Immune precipitation was used to study the humoral immune response of patients with subacute sclerosing panencephalitis (SSPE). Patients with SSPE have a progressive infection of the CNS by measles or a measles variant despite high serum antibody levels to measles virus as measured by standard serologic techniques. However, when the antibody response to individual measles virus proteins was measured, we found a striking reduction in the ability of sera from patients with SSPE to precipitate the matrix (M) protein as compared to the precipitation of the M protein by sera from normal adults who had natural measles infection in childhood, or by convalescent sera obtained 3 to 5 weeks after a naturally occurring measles infection. The decreased antibody response to the M protein in sera from patients with SSPE occurred despite a vigorous antibody response to the other viral proteins, suggesting a selective defect in the production of antibody to a single viral protein. The reduced anti-M antibody in sera from patients with SSPE was demonstrated whether immune precipitation was performed with wild-type measles virus or SSPE virus proteins. These results suggest that in SSPE only small amounts of the M protein are produced. This result may help explain how measles virus persists in the central nervous system of patients with SSPE.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 458157

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  26 in total

1.  Host-dependent temperature-sensitive growth of HVJ (Sendai virus) wild-type in rat glioma C 6 cells.

Authors:  H Ogura; H Sato; M Hatano
Journal:  Arch Virol       Date:  1987       Impact factor: 2.574

2.  Intracellular synthesis of human parainfluenza type 3 virus-specified polypeptides.

Authors:  S L Wechsler; D M Lambert; M S Galinski; M W Pons
Journal:  J Virol       Date:  1985-06       Impact factor: 5.103

3.  Structural defect linked to nonrandom mutations in the matrix gene of biken strain subacute sclerosing panencephalitis virus defined by cDNA cloning and expression of chimeric genes.

Authors:  M Ayata; A Hirano; T C Wong
Journal:  J Virol       Date:  1989-03       Impact factor: 5.103

4.  Western blot analyses of measles virus antibody in normal persons and in patients with multiple sclerosis, subacute sclerosing panencephalitis, or atypical measles.

Authors:  R W Hankins; F L Black
Journal:  J Clin Microbiol       Date:  1986-09       Impact factor: 5.948

5.  Humoral and cellular immune responses to matrix protein of measles virus in subacute sclerosing panencephalitis.

Authors:  S Dhib-Jalbut; H F McFarland; E S Mingioli; J L Sever; D E McFarlin
Journal:  J Virol       Date:  1988-07       Impact factor: 5.103

6.  Restriction of virus-specific protein synthesis in a persistent paramyxovirus infection.

Authors:  S J Robbins; F Rapp
Journal:  Arch Virol       Date:  1982       Impact factor: 2.574

7.  Human cellular immune response to measles virus polypeptides.

Authors:  J W Rose; W J Bellini; D E McFarlin; H F McFarland
Journal:  J Virol       Date:  1984-03       Impact factor: 5.103

8.  Development of antibody to measles virus polypeptides during complicated and uncomplicated measles virus infections.

Authors:  M Graves; D E Griffin; R T Johnson; R L Hirsch; I L de Soriano; S Roedenbeck; A Vaisberg
Journal:  J Virol       Date:  1984-02       Impact factor: 5.103

9.  Immune reactivity of the purified hemagglutinin of measles virus.

Authors:  W J Bellini; D E McFarlin; G D Silver; E S Mingioli; H F McFarland
Journal:  Infect Immun       Date:  1981-06       Impact factor: 3.441

10.  Antibodies against measles virus polypeptides in different disease conditions.

Authors:  E Norrby; C Orvell; B Vandvik; J D Cherry
Journal:  Infect Immun       Date:  1981-12       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.